Paradigms in the treatment of aging have evolved to address volume loss as a central and primary hallmark of the aging face. The concept of "composite volumization" was recently proposed by Dr. Z. Paul Lorenc to describe the effect of Radiesse (Merz Aesthetics, Inc., Raleigh, NC), when placed on bone in the supraperiosteal plane, on all overlying tissues (skin, superficial and deep fat compartments, and muscle). The physiochemical properties of Radiesse make it especially well suited for efficient and effective volumization of areas especially prone to volume loss; the temple, zygomatic arch, anterior cheek, pyriform aperture, and prejowl sulcus. Placement of Radiesse on bone in these areas creates a scaffold upon which additional restoration of fine lines and wrinkles may be accomplished, restoring a youthful appearance.
Since the approval of collagen in the 1970s for injection into the dermis to address facial wrinkles, nonsurgical approaches for rejuvenation have focused primarily upon filling in wrinkles and folds. In the past decade, however, our understanding of facial aging has evolved from the belief that the major contributors to aging are simple skin and superficial musculoaponeurotic system (SMAS) sagging due to gravity, to the understanding that volume loss in various facial compartments and resultant loss of soft-tissue support is the primary cause of the characteristic signs of facial aging. [1] [2] [3] [4] [5] Loss of volume in the cheeks, especially deep medial cheek fat, leads to loss of transverse width, deflation, flattening, and pseudoptosis, each of which are hallmarks of the aging face. With this improved understanding, nonsurgical treatment paradigms have evolved from strategies aimed at filling in wrinkles to a more sophisticated approach in which issues of volume loss and deflation like those observed in the flattened midface or underlying formation of deep creases within the nasolabial folds are addressed as primary concerns. 1, 6 Calcium hydroxylapatite (CaHA, Radiesse, Merz Aesthetics, Inc., Raleigh, NC) is approved by the FDA for injection into the immediate subdermal and deep subcutaneous tissue. However, off-label use in the supraperiosteal plane in areas of greatest volume loss (the temple, anterior cheek/zygoma, pyriform aperture, mandibular angle, and prejowl sulcus), best supports goals of facial "revolumization" and restoration of a youthful appearance. 4, 7 When placed directly over bone, Radiesse lifts all overlying tissues concomitantly, providing support to every layer of muscle as well as the superficial and deep fat compartments, lifting and toning the overlying skin as a single or composite unit, efficiently restoring volume to the face. 4 In the experience of the authors, injection into the supraperiosteal plane provides safe, reliable, and predictable restoration of volume, a critical first step in any treatment approach, Volume restoration should be completed prior to assessing patient need for additional complementary treatment of more superficial issues with hyaluronic acids (HAs). Here, the physiochemical properties that contribute to the utility of Radiesse in this approach of "composite revolumization," as well the authors' clinical experiences with this technique, are detailed.
Composite Lifting by Radiesse in the Supraperiosteal Plane
Within the periosteal plane, the comparatively high elastic modulus (G') and viscosity (η*) of CaHA (Table 1 ) allow it to act as a liquid implant within individual fat compartments and efficiently provide composite lift and support to overlaying tissues. 4, 8, 9 High viscosity ensures that the product is cohesive and stable once injected (Figure 1) . 4 Due to a far lower η*, even heavy HA fillers disperse, diminishing their lifting capacity. 2, 10 The high G' of Radiesse also contributes to its ability to withstand both gravitational forces and those arising from resident musculature, improving its durability and permitting substantial support to overlaying tissues.
While the physiochemical properties of Radiesse support its use in composite lifting and revolumization, the translation of these measures into injection stability (η*) and lifting capacity (G') is further supported by additional studies presented here and in other publications. 4, 9 Confirming the effect of η* on filler behavior, postinjection cadaver dissection of the malar area demonstrates that CaHA is well confined around the site of injection within the supraperiosteal plane ( Figure 1 ).
To confirm translation of high G' to lifting capacity and resultant volume expansion, pre-and postinjection images of treatment areas within two case-study patients (discussed below) were collected to permit quantitation of composite lifting achievable with Radiesse in the periosteal plane. Images were collected using a Z. One PRO Ultrasound System (Mindray Zonare Medical Systems, Mountain View, CA), and the projection of overlaying tissue was measured following injection. This study does not include follow-up ultrasounds three months following injection; however, the continued lifting capacity of Radiesse that is observed clinically coupled with the high viscosity of the filler and cadaver dissection suggest that the filler continues to remain in place.
Standard pretreatment protocols for site cleansing and marking were observed for each patient. Prior to injection, 1.5 cc of Radiesse was mixed with 0.3 mL of 1% lidocaine via a Luer-Lok device until homogeneity was achieved. The mixture was then deposited in the supraperiosteal plane with a 27-gauge, 0.75 inch needle or a 27-gauge, 1-inch blunt cannula. Posttreatment protocols of massage by the clinician in the clinical setting, but not by the patient postdischarge, and ice application were used to limit edema and ecchymosis.
Measurements of depth obtained from live images were used to calculate the percentage change in axial volume per cc of CaHA for each anatomical area, and comparison of this tissue expansion in the two case-study patients are presented in Table 2 (absolute measures of increase may be found in Lorenc and Lee 4 ). In the injected areas, Patient 1 demonstrates between a 20% and 79% increase in volume per cc of CaHA, and Patient 2 a 60% to 93% per cc volume increase. An ultrasound image of the 20% change in volume per cc of CaHA observed in the right temple of patient 1 is shown in Figure 2 , where lifting of the entire composite flap as a single unit is apparent.
The increase in axial volume measured with ultrasound ( Figure 2) , along with the observed compartmentalization in the cadaver study (Figure 1) , support the aesthetic outcomes achievable through composite lifting as shown in the case study patients presented below.
Patient 1
This 64-year-old woman received injections in both the right and left temples, malar area, pyriform apertures, and left prejowl sulcus. Injection volumes for each of these areas are listed in Table 2 , and percentage increase Table 1 . Ultrasound images of the patient's right malar before and after injection are presented in a previously published study. 4 Results of treatment are shown in Figure 3 and clearly illustrate lifting of the entire composite flap and expansion of overlaying tissues.
Patient 2
This 47-year-old woman received injections in the left and right malar area, anterior cheek, and pyriform apertures. Injection volumes for each of these areas are listed in Table 2 , and percentage increases in volume per cc of injected CaHA are listed in Table 1 . Ultrasound images of the patient's right temple before and after injection are shown in Figure 2 , and the observed composite lifting parallels that observed for patient 1. The 93% change in volume per cc of Radiesse in the midface of patient 2 is shown in an ultrasound image published elsewhere; 4 however, this dramatic change may be qualitatively appreciated in Figure 4 .
DISCUSSION
With an improvement in our understanding of the underlying causes of facial aging, treatment paradigms have evolved to address volume correction 11 rather than the filling in of wrinkles and lines. 1,2,5 Nonsurgical correction of volume loss with fillers is an important part of an approach aimed at eliminating the deflation characteristic of the aging face. Lifting and expanding skin, fat, and muscle as a single composite unit is an important foundation to be completed prior to a secondary assessment of finer lines to be filled with HA. 7 The dramatic differences between the η*and G' of HA fillers vs the η*and G' of Radiesse support the idea that these treatments should be viewed as complementary, rather than competitive, to each other. 11 The composite facial lifting achievable with Radiesse injected directly over bone in regions of the face especially prone to fat loss and deflation is measurable and directly related to its ability to provide optimal results as shown here (Figures 3 and 4) . Further, the biostimulatory effects of the calcium hydroxylapatite microspheres contribute to the durability of the treatment by promoting collagen production in the extracellular matrix. 8 The absence of significant vascular structure in the supraperiosteal plane (Figure 1 ) improve the comparative safety of Radiesse when injected over bone. [12] [13] [14] When resting directly on bone, a needle or cannula cannot also be within a vessel lumen. Of course, basic knowledge of facial anatomy, as well as knowledge of those vessels and nerves that should never be approached with a needle or cannula, is critical. A single bolus injection of appropriately diluted Radiesse in the supraperiosteal plane may spread with massage, minimizing the number of injections. The indirect effects of volumization on adjacent areas of the face may also eliminate the need for additional injections. While some may make the argument that HAs are "safer" because they are reversible, the planes into which they are most often injected have a higher risk of complications. Though higher G' HA fillers may also be used in a revolumization-based approach when injected into this plane, in the clinical experience of the authors, the higher G' of Radiesse makes it better suited for revolumization in patients for whom Radiesse is an appropriate treatment. Injecting into the supraperiosteal plane is technically straightforward, comparatively safer than more superficial planes, and highly effective. Injection of Radiesse into this plane in the forehead, for example, requires little sacrifice in the way of risk-benefit balance. Furthermore, the authors point to the skill of the practitioner as having a far greater effect on the incidence of adverse events than reversibility. In addition to its efficacy and safety, Radiesse is also versatile. An ideal agent for revolumization in a global approach, it is conducive to layering with more superficial treatment of lines with HA, fine tuning shapes over fat grafts or poly-L-lactic acid, or complementing restructuring with surgery or sutures. The versatility of CaHA is increased further by FDA approval for mixing and dilution in both the face and hands, allowing for customization based upon the individual needs of the patient or the anatomical area being treated. 15, 16 
CONCLUSION
Addressing volume loss characteristic of aging in the upper, mid, or lower face is critical for restoring a youthful appearance. For a nonsurgical approach, volume correction is the obligatory first step in facial rejuvenation. The off-label use of Radiesse in the supraperiosteal plane ensures efficient, durable "composite revolumization" in the temple, anterior cheek/zygoma, pyriform aperture, mandibular angle, and prejowl sulcus, which are areas most susceptible to volume loss, 4 and the physiochemical properties of Radiesse support this application. While these characteristics are important, treatment decisions should be made on a case-by-case basis with the anatomical area to be treated and patient characteristics in mind. Future studies of Radiesse for revolumization that include longer follow up and complementary quantitative analysis of the durability of the treatment will undoubtedly inform an educated approach to treatment selection in the revolumization of the face.
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A B Figure 4 . A 47-year-old woman (patient 2) (A) pre-and (B) 3 months posttreatment. As with patient 1, postinjection appearance is fuller, and more youthful. Reprinted with permission from Journal of Drugs in Dermatology. 4 
